PLRX revenueFY2025$0
PLRX revenue was $0 for fiscal 2025 (ended Dec 31, 2025), compared with $0 in fiscal 2024.
Pliant Therapeutics Inc. (PLRX) financials
For fiscal 2025 (ended Dec 31, 2025), Pliant Therapeutics Inc. reported $0 of revenue and -$149.34M of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$149.34M
- Free cash flow, FY2025
- -$128.71M
- EPS, diluted, FY2025
- -$2.43
- Cash
- $24.88M
- Total debt
- $0
- Market cap
- $49.5M
FY2019FY2025
FY2019FY2025
FY2019FY2025
PLRX revenue and earnings growth
PLRX net incomeQ2 2026-$22.37M
PLRX net income was -$22.37M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$43.30M a year earlier. For the full fiscal 2025 it was -$149.34M, compared with -$210.30M in fiscal 2024.
PLRX EPSQ2 2026-$0.36
PLRX diluted EPS was -$0.36 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.71 a year earlier. For the full fiscal 2025 it was -$2.43, compared with -$3.47 in fiscal 2024.
PLRX free cash flowQ2 2026-$12.80M
PLRX free cash flow was -$12.80M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$40.72M a year earlier. For the full fiscal 2025 it was -$128.71M, compared with -$159.35M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.58M | $9.69M | $7.57M | $41.82M | $57.05M |
| Research and development | $109.16M | $169.31M | $127.80M | $96.94M | $77.55M | $66.19M | $47.35M |
| Selling, general and admin | $47.22M | $59.05M | $57.93M | $39.95M | $27.56M | $17.27M | $10.93M |
| Operating income | -$156.37M | -$228.37M | -$184.15M | -$127.20M | -$97.53M | -$41.65M | -$1.23M |
| Interest expense | $2.56M | $3.02M | $1.27M | $791.0K | $0 | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | -$97.26M | -$41.53M | -$631.0K |
| EPS, basic | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| EPS, diluted | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 | -$1.95 | -$4.22 |
| Diluted shares | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 1.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.45M | $72.67M | $64.72M | $33.68M | $51.66M | $50.88M | $85.81M |
| Short-term investments | $145.50M | $284.54M | $431.01M | $297.50M | $148.93M | $226.01M | $16.97M |
| Receivables | - | - | $0 | $1.98M | $2.00M | $9.28M | $7.05M |
| Current assets | $196.45M | $362.26M | $505.50M | $340.31M | $209.44M | $290.75M | $111.90M |
| Total assets | $225.23M | $396.95M | $512.15M | $350.61M | $221.22M | $295.53M | $119.06M |
| Current liabilities | $16.36M | $33.22M | $28.52M | $23.91M | $16.83M | $11.60M | $8.17M |
| Total debt | $0 | $30.21M | $10.05M | $9.93M | $0 | - | - |
| Total liabilities | $44.02M | $92.87M | $38.58M | $37.27M | $22.16M | $12.46M | $9.08M |
| Shareholders' equity | $181.21M | $304.08M | $473.58M | $313.34M | $199.06M | $283.06M | -$76.30M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$128.34M | -$155.50M | -$116.36M | -$94.63M | -$75.44M | -$37.27M | -$2.75M |
| Capital expenditures | $374.0K | $3.85M | $921.0K | $1.76M | $1.95M | $1.53M | $964.0K |
| Free cash flow | -$128.71M | -$159.35M | -$117.28M | -$96.39M | -$77.40M | -$38.80M | -$3.71M |
| Investing cash flow | $134.29M | $140.34M | -$127.01M | -$150.20M | $73.70M | -$210.87M | -$17.93M |
| Financing cash flow | -$31.70M | $23.12M | $274.40M | $226.85M | $2.53M | $213.21M | $45.54M |
| Stock-based compensation | $26.23M | $37.63M | $44.48M | $22.60M | $10.44M | $3.90M | $1.83M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | -83.7% | 27.9% | -81.9% | -26.7% | - |
| Operating margin | - | - | -11654.7% | -1313.4% | -1288.1% | -99.6% | -2.2% |
| Net margin | - | - | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% |
| Free cash flow margin | - | - | -7422.9% | -995.3% | -1022.1% | -92.8% | -6.5% |
| Return on equity | -82.4% | -69.2% | -34.1% | -39.4% | -48.9% | -14.7% | - |
| Return on assets | -66.3% | -53.0% | -31.5% | -35.2% | -44.0% | -14.1% | -0.5% |
| Current ratio | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 |
| Debt to equity | 0.00 | 0.10 | 0.02 | 0.03 | 0.00 | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $16.73M | $13.58M | $15.59M | $17.94M | $32.20M | $43.44M | $38.79M | $47.75M | $45.62M | $37.15M | $33.18M | $32.34M |
| Selling, general and admin | $7.13M | $8.19M | $7.99M | $10.33M | $13.39M | $15.50M | $14.53M | $14.26M | $15.02M | $15.25M | $13.85M | $15.35M |
| Operating income | -$23.86M | -$21.77M | -$23.58M | -$28.27M | -$45.59M | -$58.94M | -$53.32M | -$62.01M | -$60.64M | -$52.39M | -$47.04M | -$47.69M |
| Interest expense | $0 | $0 | $136.0K | $815.0K | $809.0K | $799.0K | $834.0K | $877.0K | $868.0K | $445.0K | $321.0K | $317.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -$56.17M | -$49.73M | -$57.76M | -$55.85M | -$46.95M | -$41.11M | -$41.49M |
| EPS, basic | -$0.36 | -$0.32 | -$0.37 | -$0.43 | -$0.71 | -$0.92 | -$0.82 | -$0.95 | -$0.92 | -$0.78 | -$0.68 | -$0.70 |
| EPS, diluted | -$0.36 | -$0.32 | -$0.37 | -$0.43 | -$0.71 | -$0.92 | -$0.82 | -$0.95 | -$0.92 | -$0.78 | -$0.68 | -$0.70 |
| Diluted shares | 61.9M | 61.8M | - | 61.4M | 61.4M | 61.2M | - | 60.7M | 60.4M | 60.2M | - | 59.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.88M | $22.19M | $45.45M | $93.73M | $88.30M | $93.42M | $72.67M | $81.10M | $81.87M | $115.78M | $64.72M | $57.68M |
| Short-term investments | $133.22M | $148.70M | $145.50M | $148.06M | $176.05M | $213.71M | $284.54M | $324.90M | $356.22M | $368.09M | $431.01M | $465.93M |
| Receivables | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Current assets | $163.14M | $174.93M | $196.45M | $245.59M | $267.44M | $311.19M | $362.26M | $410.03M | $447.55M | $489.90M | $505.50M | $534.34M |
| Total assets | $189.88M | $202.60M | $225.23M | $276.60M | $299.82M | $344.77M | $396.95M | $445.67M | $483.73M | $521.61M | $512.15M | $540.46M |
| Current liabilities | $16.48M | $10.36M | $16.36M | $17.62M | $20.59M | $28.20M | $33.22M | $39.95M | $30.92M | $30.39M | $28.52M | $27.39M |
| Total debt | $0 | $0 | $0 | $30.44M | $30.36M | $30.28M | $30.21M | $30.14M | $30.07M | $30.00M | $10.05M | $10.02M |
| Total liabilities | $42.95M | $37.43M | $44.02M | $76.29M | $79.74M | $87.61M | $92.87M | $99.84M | $91.05M | $84.27M | $38.58M | $37.42M |
| Shareholders' equity | $146.93M | $165.17M | $181.21M | $200.31M | $220.08M | $257.16M | $304.08M | $345.82M | $392.68M | $437.33M | $473.58M | $503.05M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.60M | -$48.86M | -$47.66M | -$32.27M | -$45.30M | -$30.27M | -$25.10M | -$36.22M |
| Capital expenditures | $0 | $0 | $0 | $0 | $112.0K | $262.0K | $209.0K | $896.0K | $1.25M | $1.49M | $61.0K | $94.0K |
| Free cash flow | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.72M | -$49.13M | -$47.87M | -$33.17M | -$46.55M | -$31.76M | -$25.16M | -$36.32M |
| Investing cash flow | $15.49M | -$4.10M | $1.77M | $27.92M | $35.49M | $69.11M | $39.13M | $30.96M | $10.70M | $59.55M | $31.92M | $38.25M |
| Financing cash flow | $0 | $74.0K | -$32.27M | $72.0K | $0 | $498.0K | $102.0K | $543.0K | $684.0K | $21.79M | $219.0K | $699.0K |
| Stock-based compensation | $4.19M | $4.25M | $4.53M | $6.42M | $6.38M | $8.91M | $8.42M | $8.90M | $10.64M | $9.67M | $9.15M | $10.36M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | -100.0% |
| Current ratio | 9.90 | 16.89 | 12.00 | 13.93 | 12.99 | 11.03 | 10.91 | 10.26 | 14.47 | 16.12 | 17.72 | 19.50 |
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.15 | 0.14 | 0.12 | 0.10 | 0.09 | 0.08 | 0.07 | 0.02 | 0.02 |
Source: XBRL data Pliant Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PLRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PLRX | $0 | - | -$149.34M | - | $49.5M |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| INSM | $1.52B | +240.0% | -$605.61M | -39.9% | $25.47B |
| MDGL | $1.43B | +92.8% | -$155.46M | -10.9% | $10.05B |
PLRX FAQ
7 questionsWhat is PLRX revenue?
Pliant Therapeutics Inc. (PLRX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is PLRX profitable?
No. Pliant Therapeutics Inc. reported a net loss of $149.34M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PLRX have?
Pliant Therapeutics Inc. reported $24.88M in cash and cash equivalents and $0 of debt on its most recent balance sheet in SEC filings.What is PLRX free cash flow?
Pliant Therapeutics Inc. generated -$128.71M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$128.34M less capital expenditures.What is PLRX earnings per share?
Diluted earnings per share were -$2.43 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PLRX last report financial results?
The latest statements here come from Pliant Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this PLRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Pliant Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.